Updated Aug. 7, 2017 at 1:26 p.m.

Earnings: Chimerix shares rise 4 percent after beating Street

Published: 2017-08-07 13:22:00
Updated: 2017-08-07 13:26:24

Chimerix Chimerix

​Durham-based biotech company Chimerix saw its stock price rise by 4 percent on Monday after its second quarter loss beat analyst estimates.

The company, which is developing a drug to treat smallpox infections, reported a net loss of $16.7 million, or 36 cents per share, compared to a net loss of $18.1 million, or 39 cents per share, in the same quarter of 2016. Wall Street analysts were expecting a net loss of 41 cents per share.

Revenue was $675,000 for the quarter, down from revenue of $1.8 million in the second quarter of last year. Analysts were expecting revenue of $1.19 million.

“Throughout the second quarter, we continued to make steady progress as we advance brincidofovir for the benefit of immunocompromised patients,” said Chief Executive Officer M. Michelle Berrey in a statement.

Chimerix shares rose 19 cents, or 4 percent, to $4.89 in Monday morning trading.

Research and development expenses decreased to $11.6 million for the second quarter of 2017, compared to $13.8 million for the same period in 2016.

General and administrative expenses decreased to $6.3 million for the second quarter of 2017, compared to $6.6 million for the same period in 2016.

Note: This story is from the North Carolina Business News Wire, a service of the UNC-Chapel Hill School of Media and Journalism

WRAL TechWire any time: Twitter, Facebook

Copyright 2017 The University of North Carolina at Chapel Hill. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders